Medtronic, a dividend aristocrat, currently offers a near-decade high dividend yield supported by strong revenue growth in cardiovascular and neuroscience devices. The company maintains a healthy balance sheet with a net debt to EBITDA ratio below 2x and sustainable free cash flow payout ratios. Strategic investments in surgical robotics, such as the Hugo system, position Medtronic for future growth and competitiveness. Investors should watch future dividend growth rates closely as the company navigates market conditions post-2022 rate hikes.
Medtronic (MDT) menerima peringkat beli dengan target harga $92. Ini didasarkan pada panduan konservatif untuk tahun fiskal 2027 dan platform pertumbuhan yang tangguh. Perusahaan mencatat pendapatan $36,4 miliar pada tahun fiskal 2026, pertumbuhan te...
A new report reveals the surgical navigation system market, valued at $8.38 billion in 2024, is projected to grow to $18.47 billion by 2030 with a 14% CAGR. Key growth drivers include AI-guided support, augmented reality, and robotic integration, par...
